Freeline Therapeutics (FRLN) Set to Announce Quarterly Earnings on Wednesday

Freeline Therapeutics (NASDAQ:FRLN) will be releasing its earnings data on Wednesday, November 22nd.

Freeline Therapeutics Stock Performance

NASDAQ:FRLN opened at $5.76 on Tuesday. Freeline Therapeutics has a 52-week low of $2.11 and a 52-week high of $10.20. The stock has a fifty day moving average of $4.43 and a 200 day moving average of $3.77. The firm has a market capitalization of $25.00 million, a price-to-earnings ratio of -0.69 and a beta of 0.39.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on FRLN. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Freeline Therapeutics in a research report on Thursday, August 17th. Wedbush lowered shares of Freeline Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $8.00 to $5.00 in a research report on Wednesday, October 18th.

Hedge Funds Weigh In On Freeline Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp purchased a new position in shares of Freeline Therapeutics during the 2nd quarter valued at about $40,000. Federated Hermes Inc. lifted its holdings in shares of Freeline Therapeutics by 50.0% in the 1st quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $67,000 after acquiring an additional 20,000 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Freeline Therapeutics in the 1st quarter worth approximately $30,000. Renaissance Technologies LLC boosted its stake in shares of Freeline Therapeutics by 17.4% in the 1st quarter. Renaissance Technologies LLC now owns 230,600 shares of the company’s stock valued at $105,000 after purchasing an additional 34,210 shares in the last quarter. Finally, UBS Group AG bought a new position in shares of Freeline Therapeutics during the 1st quarter valued at $565,000. 46.26% of the stock is currently owned by hedge funds and other institutional investors.

About Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease.